CHMP backs Boehringer’s Spevigo for preventing rare psoriasis flare-ups – Pharmaceutical Technology
The EMA’s CHMP has approved the expansion of the label for Boehringer Ingelheim’s Spevigo (spesolimab) to include younger patients. Credit: Shutterstock/T. Schneider The European Medicine